Efficacy and safety of netarsudil 0.02% ophthalmic solution in patients with open-angle glaucoma and ocular hypertension

Berryman, Jefferson; Novack, Gary D.

doi:10.1080/17469899.2019.1645008

Cited by 2 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Various clinical studies corroborated the clinical efficacy of netarsudil across a range of eye pressures; hence it is a valuable addition to the arsenal of ocular hypotensive medications. 36 Based on the results of clinical trials, Aerie Pharmaceuticals developed a new drug combination comprising 0.02% netarsudil (ROCK inhibitor) plus 0.005% of latanoprost (PGF2α analogue), referred to as PG324. 17,37 This study showed certain common adverse effects, including eye redness, inflammation, dryness, pain, blurred vision, swelling around the eyes and headache.…”

Section: Clinical Studiesmentioning

confidence: 99%

Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension

Batra¹,

Gupta²,

Nair

et al. 2021

European Journal of Ophthalmology

View full text Add to dashboard Cite

Background: Vision impairment remains a major health problem worldwide. Elevated intraocular pressure is a prime risk factor for blindness in the elderly. Netarsudil is a Rho-associated protein kinase (ROCK) inhibitor, which also inhibits norepinephrine transport. This narrative review summarizes the properties and clinical significance of netarsudil, a promising drug in topical glaucoma therapy. Methods: We searched PubMed, Medline and Scopus databases using relevant keywords to retrieve information on the physicochemical properties, formulation, mechanism of action, clinical pharmacokinetics, dose and toxicity of netarsudil. Results: Netarsudil showed promising effects in lowering the elevated intraocular pressure by two mechanisms. The US FDA approved netarsudil for clinical use in 2017 under the trademark of Rhopressa® while European Medicines Agency approved Rhokiinsa® in 2019. This drug is available as a 0.02% ophthalmic solution for once-daily topical application. Conclusion: The discovery of netarsudil is a breakthrough in the therapy of glaucoma with proven efficacy in a wide range of eye pressures and is well tolerated in cases with ocular hypertension and chronic glaucoma.

show abstract